<DOC>
	<DOCNO>NCT00504660</DOCNO>
	<brief_summary>The goal clinical research study learn combination 6-Thioguanine , Xeloda ( capecitabine ) , Celebrex ( celecoxib ) Temodar ( temozolomide ) Lomustine ( CCNU ) effective treatment recurrent progressive anaplastic glioma glioblastoma multiforme patient fail previous treatment . The safety combination treatment also study . Objectives : 1.1 To determine efficacy , measure 12 month progression-free survival , TEMOZOLOMIDE CCNU 6-THIOGUANINE follow CAPECITABINE CELECOXIB treatment patient recurrent and/or progressive anaplastic glioma glioblastoma multiforme . 1.2 To determine long-term toxicity TEMOZOLOMIDE CCNU 6-THIOGUANINE follow CAPECITABINE CELECOXIB recurrent anaplastic glioma glioblastoma multiforme patient treat manner . 1.3 To determine clinical relevance genetic subtyping tumor predictor response chemotherapy long term survival</brief_summary>
	<brief_title>6-TG , Capecitabine Celecoxib Plus TMZ CCNU Anaplastic Glioma Patients</brief_title>
	<detailed_description>Capecitabine drug damage DNA ( deoxyribonucleic acid ) tumor cell block function DNA RNA ( ribonucleic acid ) tumor cell . These action help kill tumor cell . Celecoxib drug may help prevent development type cancer block type enzyme ( COX-2 ) find tumor cell . Temozolomide CCNU current standard treatment malignant brain tumor . Both drug work damage DNA ( deoxyribonucleic acid ) tumor cell kill tumor cell . 6-Thioguanine drug help increase effect Temozolomide CCNU tumor cell . Depending previous treatment receive , treat accord Arms 1 , 2 , 3 . If receive temozolomide , treat Arm 1 . If receive temozolomide radiation therapy chemotherapy afterwards treatment 6 month ago , treat temozolomide accord Arm 1 . If receive lomustine carmustine , treat Arm 2 . If receive Gliadel wafer surgery great 6 month ago treat lomustine carmustine , treat CCNU accord Arm 2 . Arm 3 include glioblastoma multiforme patient may treat either temozolomide lomustine accord guideline regimen describe Arms 1 2 . Arm 1 : Treatment begin 6-thioguanine take mouth 4 time day ( every 6 hour ) 3 day row ( Days 1-3 ) . This follow temozolomide take mouth bedtime 5 day row ( Days 4-8 ) . After rest period 6 day , capecitabine celecoxib take mouth twice day ( 12 hour apart ) 14 day ( Days 14-27 ) . Each cycle treatment arm 1 28 day . Arm 2 : Treatment begin 6-thioguanine take mouth 4 time day ( every 6 hour ) 3 day row ( Days 1-3 ) . This follow lomustine take mouth bedtime 1 day ( Day 4 ) . After rest period 1 week , capecitabine celecoxib take mouth twice day ( 12 hour apart ) 14 day ( Days 11-24 ) . Each cycle treatment arm 2 take 42 day . Blood test ( less 2 teaspoon ) repeat every 2 week new cycle treatment ( total 2 tablespoon ) . The neurological exam , anticonvulsant level blood test stool test blood , repeat every cycle Arms 2 3 ( CCNU ) every 2 cycle Arms 1 3 ( temozolomide ) . Kidney function evaluate blood test every course . Patients take anticoagulant ( coumadin , warfarin ) procedures test clot ability blood cycle frequently doctor feel necessary . Arm 3 : Glioblastoma Multiforme patient treat Arm 3 include drug regimen either Arm 1 Arm 2 . Treatment arm continue 1 year long tumor grow side effect tolerable . Treatment may continue beyond one year doctor feel need . During study , may receive investigational drug treatment cancer , include surgery . This investigational study . All drug use study FDA approve commercially available . A total 140 patient take part study . All patient enrol M. D. Anderson .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1 . All patient must sign informed consent indicate aware investigational nature study keep policy hospital . 2 . Patients histologically prove supratentorial anaplastic oligodendrogliomas , anaplastic mixed oligoastrocytomas anaplastic astrocytomas glioblastoma multiforme . 3 . Patients must unequivocal evidence tumor recurrence progression MRI scan perform within 14 day prior enrollment document recurrence tumor resection . Patients must receive radiation therapy previously . 4 . Patients undergone recent resection recurrent progressive tumor eligible long follow condition meet : ) Patients recovered effect surgery ; b ) Extent residual disease ( present ) document MRI perform later 72 hour surgery , possible , least 4 week postoperative . Radiographic evidence residual disease mandate enrollment . 5 . The baseline onstudy MRI perform within 14 day enrollment steroid dosage stable . If steroid dose increase date imaging initiation chemotherapy , new baseline MRI require stable steroid 7 day . 6 . Patients must equal great 12 year old . 7 . Patients must Karnofsky performance status equal great 60 ( Karnofsky Performance Scale ; Appendix D ) . 8 . Patients must recover toxic effect prior therapy : 4 week prior cytotoxic therapy and/or least two week vincristine , 6 week nitrosoureas , 3 week procarbazine administration , 1 week noncytotoxic agent , e.g. , interferon , tamoxifen , thalidomide , cisretinoic acid , etc . ( radiosensitizer count ) . Any question relate definition noncytotoxic agent direct Study Chair . 9 . Patients must adequate bone marrow function ( ANC equal great 1,500/mm3 platelet count equal great 100,000/mm3 ) , adequate liver function ( SGPT alkaline phosphatase &lt; 2 time normal , bilirubin &lt; 1.5 mg % ) , adequate renal function ( BUN creatinine &lt; 1.5 time institutional normal ) prior start therapy . 1 . Patients history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) , unless complete remission therapy disease minimum 3 year ( 1 year localize prostate carcinoma treat prostatectomy irradiation ) ineligible . 2 . Patients childbearing potential must pregnant become pregnant . 3 . Patients must : ) active infection ; b ) disease obscure toxicity dangerously alter drug metabolism ; c ) serious intercurrent medical illness ; ) acute chronic pulmonary disease , pulmonary embolus , hypertension , diabetes , metabolic syndrome , stroke , heart disease , myocardial infarction , angina , coronary angioplasty , congestive heart failure , coronary bypass surgery ; e ) allergy sulfa drug ; f ) severe psychiatric illness ; g ) uncontrolled hypertension ( i.e . &gt; 135/ &gt; 85 mm Hg ) three repeat measurement 6 week prior enrollment study 4 . Patients must ( continue ) : h ) family history premature coronary disease ( i.e . onset &lt; 55 year age ) ; ) uncontrolled hypercholesteremia [ lowdensity lipoprotein cholesterol ( LDLC &gt; 130 ] . Hypercholesteremia must control least 3 month prior enrollment study ; j ) history systemic lupus erythematous , family history protein S C deficiency , prior heparininduced thrombocytopenia , Factor V Leiden deficiency high homocysteine level ; k ) indication ASA deficiency 5 . Patients must prior treatment Capecitabine , 5FU combination Temozolomide CCNU ( Lomustine ) BCNU ( Carmustine ) . Patients receive Temozolomide radiation therapy receive adjuvant chemotherapy Temozolomide and/or receive Gliadel ( BCNU ) wafer surgery without adjuvant chemotherapy BCNU CCNU eligible 6 month pass since treatment ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Anaplastic Glioma</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>6-Thioguanine</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Celecoxib</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Xeloda</keyword>
	<keyword>Temodar</keyword>
	<keyword>TMZ</keyword>
	<keyword>CCNU</keyword>
	<keyword>6-TG</keyword>
</DOC>